A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)

• Status: Completed
• Trial end date: 2012-05-01

Summary

The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in subjects who have active rheumatoid arthritis and have been treated previously with at least 1 dose of a biologic anti-TNFa agent (etanercept, adalimumab or infliximab).

• Phase: Phase 3

Details

• Lead Sponsor: Centocor, Inc.
• Collaborator: Schering-Plough
• Treatments: Antibodies, Monoclonal; Golimumab